Celldex Therapeutics reported $7.15M in Selling and Administration Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbvie ABBV:US $ 3.13B 73M
Agenus AGEN:US $ 18.91M 39K
Amgen AMGN:US $ 1.33B 99M
Applied Genetic Technologies AGTC:US $ 4.32M 494K
Biocept BIOC:US $ 10.47M 5.22M
Bristol Myers Squibb BMY:US $ 1.78B 46M
Celldex Therapeutics CLDX:US $ 7.15M 243K
Cytrx CYTR:US 51.91K 1.93M
Glaxosmithkline GSK:US 1.96B 726M
Immunogen IMGN:US $ 23.79M 7.14M
Merrimack Pharmaceuticals MACK:US $ 486K 91K
Nektar Therapeutics NKTR:US $ 21.44M 5.9M
Newlink Genetics NLNK:US 3.62M 193K
Northwest Biotherapeutics NWBO:US 7.87M 1.38M
Pfizer PFE:US $ 3.2B 506M
Rigel Pharmaceuticals RIGL:US $ 26.98M 420K
Seattle Genetics SGEN:US $ 220.26M 46.03M